Product
Chemotherapy monitoring by circulating tumor DNA analysis
1 clinical trial
1 indication
Indication
HER2-negative Metastatic Breast CancerClinical trial
Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 StudyStatus: Recruiting, Estimated PCD: 2026-10-01